Combined pathologic‐genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay

BACKGROUND: The 21-gene recurrence score (RS) (Oncotype DX(®); Genomic Health, Redwood City, CA) partitions hormone receptor positive, node negative breast cancers into three risk groups for recurrence. The Anne Arundel Medical Center (AAMC) model has previously been shown to accurately predict RS r...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Oncol
Glavni autori: Gage, M M, Mylander, W C, Rosman, M, Fujii, T, Le Du, F, Raghavendra, A, Sinha, A K, Espinosa Fernandez, J R, James, A, Ueno, N T, Tafra, L, Jackson, R S
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Original articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5961181/
https://ncbi.nlm.nih.gov/pubmed/29788166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy074
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items